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Reply to P.F. Pinsky, C.P. Crum, and
M.W. McIntosh et al
We welcome the opportunity to respond to comments raised
by colleagues in the ﬁeld to our recent publication.1 We thank
Crum2 for his interest and insights. He highlights that high-
grade serous carcinomas may arise through two routes: one from
precursor lesions in the fallopian tube, such as serous tubal intra-
epithelial carcinoma, and the other from as-yet undeﬁned
Mullerian sources. The site of origin would determine the extent to
which opportunistic salpingectomy may protect women. We share
the view of Crum that this is a key issue, given the increasing
popularity of this procedure as a preventive measure. We seek to
address this through a randomized controlled trial.
Crum2 is correct that United Kingdom Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS) could have provided a
unique perspective on the origins of ovarian cancer, because
women with screen-detected ovarian/tubal/primary peritoneal
cancers were diagnosed earlier in their disease evolution than
were symptomatic patients in clinical case series. However, the
trial was designed in 2000, before the emergence of the dualistic
model of high-grade serous carcinomas. Therefore, at surgery,
there was no recommendation or funding for the tubes and
ovaries to be subjected to the sectioning and extensively
examining of the ﬁmbriated end (SEE-FIM) protocol, which was
formally described in 2006.3 We are in the process of collating
tissue blocks fromwomen diagnosed with ovarian/tubal/primary
peritoneal cancer during the course of the trial for further
research. At this stage, we are unable to estimate what proportion
of the tumors might be available for detailed pathologic
examination of the fallopian tube; however, we, like Crum,
remain hopeful that there will be an eligible subset.
We would like to raise one point of clariﬁcation. Crum2 states
that follow-up studies will be required to establish whether the out-
come of multimodal screening will improve survival. The primary
outcome measure of UKCTOCS is disease-speciﬁc mortality,
and we will be reporting this at the end of the year.
The concerns of Pinsky4 are related to our deﬁnition of speciﬁc-
ity. He suggests that speciﬁcity should be based on the results of the
primary screening. We have a major difference of opinion in this
regard. We share the United Kingdom National Population Screening
Programme principle that screening is a process5 that consists of
multiple steps and not just of the primary screen. For population
screening to be effective, the entire process needs to be centrallymanaged
with a strict, time-dependent protocol and quality assurance. In
keeping with this, all participants in UKCTOCS consented to the whole
process and not to a single test. We, therefore, have reported the
performance characteristics for multimodal screening in its entirety.
Although we agree with Pinsky4 that it is important to
describe the proportion of women who would need repeat testing,
we do not agree this should be the primary measure of speciﬁcity.
At the start of the trial, we calibrated the risk cutoffs after the
primary screening so that 10% to 15% of women would be at
intermediate risk of ovarian cancer and would have a repeat blood
test, and 2% of women would be at elevated risk of ovarian cancer
and would go on to have a transvaginal scan and repeat blood test.
This was described in the patient information sheet and was known
to volunteers before they consented to participate.
Pinsky4 is correct that any screening result that requires
follow-up, including a repeat screen, carries potential harms and
costs and should be counted. Thus, an independent psychosocial
study has been undertaken alongside UKCTOCS to assess potential
harm at each stage. Findings suggest that screening did not raise
anxiety and that repeat tests after the annual screening, overall
number of repeat tests, and more intensive screening (eg, trans-
vaginal scan and blood test v repeat blood test) did not signiﬁcantly
affect anxiety compared with routine annual screening. Surgical
procedures that, in our trial, deﬁned performance characteristics
(both sensitivity and speciﬁcity) did, however, cause changes in
anxiety.6 In addition, a separate health economic analysis will
report the cost effectiveness of the entire screening process,
including all repeat tests and not just the annual screening. The
economic analysis will be available after the publication of the
mortality results.
The ﬁrst issue that McIntosh et al7 raise relates to our title
and core message, which they suggest are misleading. We would
like to clarify that these reﬂect the actual results of the largest-ever
prospective trial of multimodal ovarian cancer screening, which
involved 296,911 annual incidence screenings in 46,237 women.
We strongly believe that the comparison of our outcomes to what
has been previously achieved with ovarian screening in the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial,8
for which a single-threshold (ST) rule was applied, was essential
to assess whether any progress had been made. Ultimately, the
effectiveness of screening depends on its impact on mortality, and
our group has led the effort to deliver a deﬁnitive answer. The
mortality impact publication should be available by the end of
this year.
Although some of the group have an associationwith Abcodia,
which is commercializing the Risk of Ovarian Cancer Algorithm
(ROCA), the company was not in any way involved in the funding
or conduct of UKCTOCS and had no inﬂuence on the analysis and
interpretation of our data.
McIntosh et al7 state that sensitivity and speciﬁcity were not
calculated in a compatible fashion. Asmentioned in the response to
remarks by Pinsky, screening is a process, and we clearly stated the
sensitivity (85.8%) and speciﬁcity (99.8%) of the multimodal
approach for detection of invasive epithelial ovarian cancer (iEOC)
in the abstract. We then went on to compare the STrule and ROCA
on the primary screen, and we stated that ROCA detected 87.1% of
the iEOC and that the ST rule would have identiﬁed 41.3% to
66.5%, depending on the cutoff value. No speciﬁcity was stated for
either. In the Results section and in Figure 4 of our article,1
sensitivity and speciﬁcity for ROCA and the ST rule at multiple
cutoffs are clearly provided: sensitivity of ROCA at annual
screening was 87.1% (95% CI, 80.8% to 91.9%), and speciﬁcity
was 87.6%, and those of the ST rule with an annual CA-125 cutoff
of 20.99 U/mL were 68.4% (95% CI, 58.4% to 73.8%) and 87.6%,
respectively.
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McIntosh et al7 correctly noted that women should not inter-
pret ROCA sensitivity or detection rates to mean that 85.8% of
screening-detected iEOCs are treated before symptoms arise. As is
well known in the context of screening, symptoms are reported by a
proportion of apparently well individuals who present for screening.
This is likely to be magniﬁed in the context of ovarian cancer, for
which the symptoms are ill deﬁned despite signiﬁcant efforts. We have
already undertaken a detailed analysis of the presence of symptoms in
women with screening-detected ovarian/tubal/peritoneal cancers in
UKCTOCS, and this analysis has been accepted for presentation at the
European Society of Gynaecological Oncology (ESGO) annual meet-
ing in October 2015.
We regret the attempt by McIntosh et al7 to extract and analyze
incomplete data from our published ﬁgure. This does not align with
the academic spirit in which we and others offer data for publication
in scientiﬁc journals. UKCTOCS is ongoing (follow-up until 2024),
and the trial team is currently undertaking numerous analyses of
the data. In due course, we hope to collaborate with interested
researchers. Furthermore, the presented analysis is ﬂawed, because the
authors have no access to the ROCA risk classiﬁcation of previous
annual screens. McIntosh et al7 assumed that the ROCA-derived risk
was normal on previous screens. This is incorrect. A blinded com-
parison of published and new serial algorithms with the entire
UKCTOCS multimodal data set was planned in 2011 as part of our
ongoing research efforts to improve ovarian cancer screening strat-
egies and is almost complete. A publication with an accurate com-
parison of different strategies should be freely available early next year.
We agreewithMcIntosh et al7 on theneed todevelop strategies to
manage elevated risk on the basis of serial marker levels and negative
imaging. This has been a core issue that we have tackled and discussed
widely in internationalmeetings since the start of UKCTOCS in 2001.
In the trial, we recommended surgery if the risk was 1 or greater in 5
despite normal cross-sectional imaging. The authors suggest that new
molecular imaging techniques are the only way forward. Although
these techniques are an avenueworth exploring, we are of the opinion
that much can also be gained by the exploration of serial change
in other markers alongside CA-125. This is being systematically investi-
gatedin ablinded case-control study that uses all of the serial samples
fromwomen in themultimodal groupwhohave developed ovarian/
tubal/peritoneal cancers in the course of UKCTOCS.
In conclusion, UKCTOCS deﬁnitively demonstrates that
multimodal screening with ROCA detects ovarian cancer with high
sensitivity and speciﬁcity. Later this year, we will know whether this
translates into a reduction in ovarian cancer mortality.
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